Franklin Resources Inc. Purchases 23,594 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Franklin Resources Inc. raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,776,880 shares of the biopharmaceutical company’s stock after purchasing an additional 23,594 shares during the quarter. Franklin Resources Inc. owned 1.67% of Intra-Cellular Therapies worth $148,405,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter worth $96,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $97,000. Quarry LP increased its stake in shares of Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Barlow Wealth Partners Inc. bought a new position in Intra-Cellular Therapies in the 4th quarter worth $184,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of Intra-Cellular Therapies stock opened at $131.91 on Thursday. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.98. The stock has a 50 day moving average of $129.43 and a 200 day moving average of $100.82. The firm has a market cap of $14.05 billion, a PE ratio of -151.62 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. As a group, equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on ITCI shares. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.